Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) announced positive secondary findings from the first of four Phase 3 trials of its lead ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE